Mefitel film for radiation dermatitis: it works, why not?

Published Date: 13 Mar 2023

According to the results of a phase 3 trial, the use of silicone film before radiotherapy can reduce the incidence of radiodermatitis, so why not use it?

Read Full News

Latest News

Make the Diagnosis: This Cyst Is Asymptomatic. Is It a Problem?

A 67-year-old man visited the doctor for a cyst-like lesion that developed on his face 3 months prior.

Targeted Oral Drug Plus UV Therapy May Help in Extensive Vitiligo

Positive signs in phase II test

Novel Drug Eases Disease Activity in Dermatomyositis

Dazukibart targets specific molecular pathology of chronic systemic autoimmune disease

Biomarker May Flag Humira Responders in Hidradenitis Suppurativa

Patients' C-reactive protein levels also reflect significantly higher BMI and disease severity

What Botox Teaches Us About Serendipity in Clinical Encounters

Don't forget the power of a strong doctor-patient relationship

Make the Diagnosis: Are Her Nail Symptoms Part of a Larger Picture?

A 62-year-old woman visited her doctor about thick, crumbling, discolored toenails that developed over many months. Can you diagnose the patient?

Todays Updates

The Skin–Brain Axis: Emerging Evidence Transforming Dermatologic Care Lisa A. Swanson, MD, Enzo Berardesca, MD, Mohammad Jafferany, MD

Research reveals a significant skin-brain connection, linking inflammatory skin diseases to neurocognitive and emotional health, particularly in children with atopic dermatitis.

Phase 2 Study of Lenadogene Nolparvovec Gene Therapy for Leber Hereditary Optic Neuropathy: The REVISE Trial Isabella Ciccone, MPH

The REVISE trial, a phase 2 study evaluating GenSight Biologics’ lenadogene nolparvovec in patients with Leber hereditary optic neuropathy, is expected to begin in January 2026.

FDA Lifts Clinical Hold on Intellia’s Trial for Gene Editing Therapy Nex-Z in ATTRv-PN, Places Holds on REGENXBIO MPS Trials Noah Stansfield

Intellia’s trial for nex-z in ATTR-CM remains under clinical hold.

Navigating Opportunities and Obstacles in Gastroparesis, With Ronen Arai, MD Ronen Arai, MD

Arai breaks down key recommendations from the 2025 AGA gastroparesis guidelines and what they mean for the field at large.

IMMpactful: Risankizumab Shows Greater Clinical Response to Deucravacitinib in Psoriasis

IMMpactful: Risankizumab Shows Greater Clinical Response to Deucravacitinib in Psoriasis

Todays Updates

The Skin–Brain Axis: Emerging Evidence Transforming Dermatologic Care Lisa A. Swanson, MD, Enzo Berardesca, MD, Mohammad Jafferany, MD

Research reveals a significant skin-brain connection, linking inflammatory skin diseases to neurocognitive and emotional health, particularly in children with atopic dermatitis.

Phase 2 Study of Lenadogene Nolparvovec Gene Therapy for Leber Hereditary Optic Neuropathy: The REVISE Trial Isabella Ciccone, MPH

The REVISE trial, a phase 2 study evaluating GenSight Biologics’ lenadogene nolparvovec in patients with Leber hereditary optic neuropathy, is expected to begin in January 2026.

FDA Lifts Clinical Hold on Intellia’s Trial for Gene Editing Therapy Nex-Z in ATTRv-PN, Places Holds on REGENXBIO MPS Trials Noah Stansfield

Intellia’s trial for nex-z in ATTR-CM remains under clinical hold.

Navigating Opportunities and Obstacles in Gastroparesis, With Ronen Arai, MD Ronen Arai, MD

Arai breaks down key recommendations from the 2025 AGA gastroparesis guidelines and what they mean for the field at large.

IMMpactful: Risankizumab Shows Greater Clinical Response to Deucravacitinib in Psoriasis

IMMpactful: Risankizumab Shows Greater Clinical Response to Deucravacitinib in Psoriasis

Latest News

A 67-year-old man visited the doctor for a cyst-like lesion that developed on his face 3 months prior.

Positive signs in phase II test

Dazukibart targets specific molecular pathology of chronic systemic autoimmune disease

Patients' C-reactive protein levels also reflect significantly higher BMI and disease severity

Don't forget the power of a strong doctor-patient relationship

A 62-year-old woman visited her doctor about thick, crumbling, discolored toenails that developed over many months. Can you diagnose the patient?

News All Time

Novel Drug for Chronic Inducible Urticaria Delivers in Mid-Stage Trial

Impressive responses with barzolvolimab in cold urticaria, symptomatic dermographism

Dupilumab Proves Effective in Chronic Spontaneous Urticaria

Significant reduction in hives and itch in antihistamine-resistant patients

50 Years After City Halted Prison Medical Testing, Families Seek Reparations

"No amount of money can replace what was done to me," said one former prisoner

Make the Diagnosis: She Feels Fine, But Why Do Her Fingers Look Like This?

A 38-year-old woman visited her doctor about itchy, raised spots that developed on her fingers 5 days prior. Can you diagnose the patient?

A Look at Kamala Harris' Medical History

Veep in "excellent health," doctor says, with history that includes seasonal allergies, urticaria

Selective Role for Single-Agent Ipilimumab After Anti-PD-1 Failure in Melanoma

Two-year survival in second line for patients with BRAF/NRAS wild-type tumors

Acne Treatments Taken Right Off the Shelf Had High Levels of Benzene

Study findings suggest cold storage may prevent breakdown into carcinogen

Make the Diagnosis: It’s Ugly, and It Hurts. What the Heck Is It?

A 29-year-old woman visited the doctor for a painful rash that developed on her arm 1 day after working on a landscaping project that involved pulling weeds under intense sunlight. Can you diagnose the patient?

Hitting Psoriatic Arthritis Early With Apremilast Helps Some Patients, Trial Finds

But only a minority achieved minimal disease activity within 16 weeks

Lebrikizumab Wins FDA Approval for Eczema

38% of patients treated with IL-13 blocker achieved clear or almost-clear skin at 16 weeks

Higher Steroid Dose for ICI Toxicity Harms Cancer Survival, Analysis Suggests

More data for discussion of controversial association between steroids, immunotherapy

Stopping JAK Inhibitor for Severe Alopecia Areata Led to Hair Loss

Long-term maintenance therapy is necessary, researchers caution

IL-31 Drug for Itchy Nodular Skin Disease Gets Thumbs Up From FDA

Nemolizumab significantly improved itch, nodules, and sleep disturbance at 16 weeks

IL-2 Receptor-Targeted Therapy Approved for Relapsed/Refractory CTCL

New iteration of denileukin diftitox led to objective responses in 36% of pretreated patients

Psoriasis Control Maintained Long Term With Extended Dosing Interval of Guselkumab

More than 90% of patients met response criteria at 68 weeks with 8- or 16-week dosing

Common Antibiotics Linked With Serious Skin Reactions in Older Adults

Sulfonamides and cephalosporins the worst offenders, study finds

Recommended News For You

New study highlights success of financial toxicity tumor board in reducing cancer treatment costs

FDA Bans Red Dye No. 3 From Foods, Ingested Drugs

Study: Pre-operative THP leads to pCR in 64% of early-stage HER2+ ER- breast cancer patients

Studies point to redlining as a 'perfect storm' for breast cancer

Congress Ditched Fix to Medicare Doc Pay Cut in Skinny Budget Bill

high response rate when using a bispecific antibody to treat R/R multiple myeloma.

Gene Therapy for Hemophilia B Significantly Outperforms Factor IX Prophylaxis

Recommended Articles For You

Exploring the Latest Advances in PTLD Cancer Treatment 

Multidisciplinary Insights into Diagnosis, Management, and Outcomes in Oncology 

Everything You Need to Know About RDW-CV: A Comprehensive Guide  

Anesthetic Techniques and Strategies in Cancer Surgery: Unveiling the Impact on Oncological Outcomes 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

For elderly, unfit patients, the all-oral AML regimen shows promise.

2.

Adaptive SABR-Used Hypofractionated Chemoradiation Showed Good Results in NSCLC.

3.

Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma

4.

Experts Debate AQUILA Trial Findings in Smoldering Multiple Myeloma

5.

The discovery of drug combinations may increase the life expectancy of children with brain cancer.

1.

Optimizing Melanoma Treatment: Strategies in Diagnosis, Clinical Research, and Physician Training

2.

Early Detection of Breast Cancer: Signs, Symptoms, and Screening Methods

3.

Uncovering the Hidden Signs: How to Recognize the Early Symptoms of Colon Cancer

4.

Cracking the Code of Subdural Hematomas: Modern Strategies for Optimal Care

5.

Unlocking the Secrets of Ringed Sideroblasts: A New Frontier in Hematology

1.

International Lung Cancer Congress®

2.

Future NRG Oncology Meeting

3.

Genito-Urinary Oncology Summit 2026

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII

2.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)

3.

Oropharyngeal Cancer in Relation to HPV Status

4.

An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion- Part II

5.

Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC


Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot